ClinicalTrials.gg
RecruitingNCT06378060Updated Apr 22, 2024

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

A Phase 2 interventional study of Modified transplantation system in Severe Aplastic Anemia, sponsored by Hematology department of the 920th hospital. Recruiting at 1 site in China. Open to participants aged 3 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Hematology department of the 920th hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
3 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 89 studies in Anemia, Aplastic with a site in China — 40 open to participants now, 44 under way, 1 of them phase 3. Anemia, Aplastic · China.

Planned enrollment
56th of 74
30 · median 52
Started
2024
with 10 others
Phase 2
26 of 89
10 open now
Primary completion
2026-04
later than 17 of 43 live
Registered
55th of 89
by date
Lead sponsor
2 of 89
Hematology department of the 920th hospital

Among the 89 studies in Anemia, Aplastic with a site in China, this one is the 56th largest by planned enrollment of the 74 interventional ones that give a count, is one of 11 that started in 2024, is one of 26 in phase 2, reaches primary completion later than 17 of the 43 other live ones, and was the 55th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

40 of the 89 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 3 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Anemia, Aplastic with a site in China, or all of them as a file.
02

Study summary

The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.

Read the detailed description

ObjectiveTo evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen in aplastic anemia. Aplastic anemia (AA) is a group of myelo-hemopoietic failure syndromes caused by a variety of etiologies. If not intervened, the average expected survival time is less than half a year.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the possible cures for this disease. The success rate of treatment for this disease can be further improved under the previous regimen system. The survival rate reported in the literature is 60%-90%. We designed this study to improve the conditioning regimen and optimize the GHVD prevention measures to improve the transplant success rate and prolong patient survival, while minimizing the occurrence of GVHD and reducing the recurrence rate of the disease.30 patients with aplastic anemia were planned to be enrolled.

03

Conditions studied

  • Severe Aplastic Anemia

Browse trials for

Keywords

  • Severe Aplastic Anemia
  • Modified transplantation system
  • Ruxolitinib
  • Melphalan
04

Who can participate

Ages eligible
3 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with benign or malignant hematological diseases such as leukemia, lymphoma, thalassemia, aplastic anemia, etc. diagnosed by NCCN guidelines, and requiring hematopoietic stem cell transplantation as determined by the researchers;
  2. Age 3-65 years old;
  3. Weight 10Kg-100Kg;
  4. (ECOG) score ≤3;
  5. No major organ injury ( >45%; \< 2 times the value; and ALT \< 3 times the upper limit of normal value; serum creatinine \< 2 times the upper limit of normal value);
  6. No severe infection;
  7. Subjects voluntarily participated in this clinical trial and signed the .

Exclusion criteria

Exclusion Criteria:

  1. patients with nonhematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation;
  2. patients with an expected survival of less than 1 month;
  3. patients with previous or allogeneic hematopoietic stem cell transplantation;
  4. pregnant patients;
  5. patients with severe mental or neurological disorders that would affect the ability to provide and/or to report or observe adverse events;
  6. other conditions that the investigator determines to be inappropriate for enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Drug: Modified transplantation system

Interventions

  • DrugModified transplantation system

    Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA

06

What researchers measure

Primary outcomes

  1. overall survival (OS)

    2-year overall survival (OS) and graft-versus-host disease and relapse-free survival (GRFS) after transplantation

    Time frame: [Time Frame: 2 years after allogeneic transplantation with improved conditioning regimen]

  2. Acute graft-versus-host disease incidence

    Time frame: [Time Frame: 2 years after allogeneic transplantation with improved conditioning regimen]

Secondary outcomes

  1. Transplantation-related motality

    Time frame: [Time Frame: 2 years after allogeneic transplantation with improved conditioning regimen]

  2. Chronic graft-versus-host disease incidence

    Time frame: [Time Frame: 2 years after allogeneic transplantation with improved conditioning regimen]

  3. incidence of Intensive fungal disease

    Time frame: [Time Frame: 2 years after allogeneic transplantation with improved conditioning regimen]

  4. EB virus reactivation rate

    Time frame: [Time Frame: 2 years after allogeneic transplantation with improved conditioning regimen]

  5. CMV reactivation rate

    Time frame: [Time Frame: 2 years after allogeneic transplantation with improved conditioning regimen]

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Apr 2026, 25 months after the start.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 25 months is below that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 22, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2027
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06378060
Lead sponsor
Hematology department of the 920th hospital
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Mar 1, 2024
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Apr 22, 2024

Study contacts

wang PI sanbin, Doctor
Contact
Wangsanbin2022@126.com
0871-64774206

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion